Holen Sie sich die Stockscreener-App
17.53
4.47%
0.75
Schlusskurs vom Vortag:
$16.78
Offen:
$17.11
24-Stunden-Volumen:
3.88M
Relative Volume:
1.74
Marktkapitalisierung:
$2.81B
Einnahmen:
$295.41M
Nettoeinkommen (Verlust:
$-49.64M
KGV:
-53.54
EPS:
-0.3274
Netto-Cashflow:
$-29.54M
1W Leistung:
-6.41%
1M Leistung:
+37.92%
6M Leistung:
+6.24%
1J Leistung:
+67.43%
1-Tages-Spanne:
$17.00
$17.57
1-Wochen-Bereich:
$15.90
$19.52
52-Wochen-Spanne:
$9.9551
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Firmenname
Adaptive Biotechnologies Corp
Sektor
Branche
Telefon
206-659-0067
Adresse
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
17.53 | 2.81B | 295.41M | -49.64M | -29.54M | -0.3274 |
TMO
Thermo Fisher Scientific Inc
|
464.61 | 172.66B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
177.17 | 125.40B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.09 | 44.34B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
127.06 | 35.89B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
355.44 | 34.90B | 3.77B | 449.25M | 240.68M | 7.8556 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-09-30 | Eingeleitet | Guggenheim | Buy |
| 2025-06-18 | Eingeleitet | Craig Hallum | Buy |
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-12-21 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Underperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2022-02-16 | Bestätigt | BTIG Research | Buy |
| 2022-02-16 | Bestätigt | BofA Securities | Buy |
| 2022-02-16 | Bestätigt | Goldman | Neutral |
| 2022-02-16 | Bestätigt | JP Morgan | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-03-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Eingeleitet | Goldman | Buy |
| 2019-07-23 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | BofA/Merrill | Buy |
| 2019-07-22 | Eingeleitet | Cowen | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Neutral |
| 2019-07-22 | Eingeleitet | Guggenheim | Buy |
| 2019-07-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Adaptive Biotechnologies Corp Aktie (ADPT) Neueste Nachrichten
Adaptive Biotechnologies Corp (ADPT) Institutional Confidence - TradingKey
Insider Sell: Harlan Robins Sells 106,160 Shares of Adaptive Bio - GuruFocus
Adaptive Biotechnologies Corp (ADPT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Adaptive Biotechnologies Corp (ADPT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Adaptive Biotechnologies Corp (ADPT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Adaptive Biotechnologies CSO Harlan Robins sells $1.8m in stock - Investing.com UK
Adaptive Biotechnologies Corp (ADPT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Adaptive Biotechnologies Corp (ADPT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Adaptive Biotechnologies CSO Harlan Robins sells $1.8m in stock By Investing.com - Investing.com India
Adaptive Biotechnologies (ADPT) CSO sells 106K shares under 10b5-1 plan - Stock Titan
ADPT Reiterated by BTIG -- Price Target Maintained at $22 - GuruFocus
Adaptive Biotechnologies Business Separation May Unlock Greater Value - Benzinga
BTIG reiterates Adeptus Biotechnologies stock rating on business split By Investing.com - Investing.com South Africa
Adaptive Biotechnologies Corp (ADPT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Adaptive Biotechnologies Corp - TradingKey
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering - The Manila Times
[144] Adaptive Biotechnologies Corp SEC Filing - Stock Titan
Seattle biotech looks to raise up to $288 million amid plans to spin out immune medicine business - The Business Journals
Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses - Benzinga
Stock Market Today: S&P 500, Nasdaq Futures Fall, Dow Gains Amid US-Iran Deal— SpaceX, Dave And Buster's, Western Digital In Focus (UPDATED) - Benzinga
Adaptive Biotechnologies stock falls on convertible debt plan - Investing.com
Adaptive Biotechnologies chief commercial officer sells $95,000 in shares - Investing.com
Adaptive Biotechnologies chief commercial officer sells $95,000 in shares By Investing.com - Investing.com India
Executive at Adaptive Biotechnologies (ADPT) sells 5,000 shares under 10b5-1 plan - Stock Titan
Adaptive Biotechnologies plans to separate MRD, Immune Medicine units - Investing.com
Adaptive Biotechnologies plans $250M convertible notes offering - Investing.com
Adaptive Biotechnologies stock falls on convertible debt plan By Investing.com - Investing.com India
Adaptive Biotechnologies proposes $250M convertible notes, plans MRD/Immune Medicine separation - TradingView
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering - The Manila Times
Adaptive Biotechnologies (NASDAQ: ADPT) to sell $250M converts and explore MRD–Immune Medicine split - Stock Titan
Adaptive Biotechnologies plans $250M convertible notes offering By Investing.com - Investing.com UK
Adaptive Biotechnologies plans split: MRD tests vs AI immune unit - Stock Titan
Adaptive Biotechnologies lines up $250M note deal to repay debt, buy back shares - Stock Titan
Kennedy Capital Management LLC Trims Holdings in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors? - Yahoo Finance
Adaptive Biotechnologies Momentum Lifts Nasdaq Healthcare Focus - Kalkine Media
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap UpWhat's Next? - MarketBeat
Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last? - Yahoo Finance
ADPT: Brokered notice to sell 5,000 shares (NASDAQ: ADPT) listed - Stock Titan
Adaptive Biotechnologies Corporation $ADPT Shares Sold by Amova Asset Management Americas Inc. - MarketBeat
Adaptive Biotechnologies (ADPT) shareholders back directors, pay and 2026 auditor - Stock Titan
Adaptive Biotechnologies CCO Bobulsky sells $198,000 in stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies CPO Francis Lo sells $695k in stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies CCO Bobulsky sells $198,000 in stock - Investing.com UK
Adaptive Biotechnologies CPO Francis Lo sells $695k in stock - Investing.com UK
Adaptive Biotechnologies (ADPT) CPO sells 39,741 shares after option exercises - Stock Titan
ADPT (NASDAQ: ADPT) affiliate notifies planned sale after option exercise - Stock Titan
How The Adaptive Biotechnologies (ADPT) Narrative Is Shifting Around A US$20 Fair Value Anchor - Yahoo Finance
Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference - Yahoo Finance
Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026 - Insider Monkey
10 Best Growth Stocks Under $20 to Buy - Insider Monkey
Finanzdaten der Adaptive Biotechnologies Corp-Aktie (ADPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):